Effects of tirofiban combined with metoprolol on hemodynamics and serum levels of MMP-9 and CRP in patients with acute myocardial infarction

Abstract

Objective To investigate the effects of tirofiban combined with metoprolol on hemodynamics and serum levels of C-reactive protein (CRP) and matrix metalloproteinase-9 (MMP-9) in patients with acute myocardial infarction (AMI). Methods 82 patients with AMI treated at our hospital from December, 2013 to June, 2016 were randomly divided into a control group and a study group, 41 for each group. Both groups were treated with conventional anticoagulant thrombolytic therapy and expansion of coronary artery after admission; on the basis of this, the control group were treated with metoprolol for 7 d and the study group with metoprolol and tirofiban (continuously pumping for 36 h). The clinical efficacy, incidence of adverse reactions, hemodynamic parameters [mean pulmonary artery pressure (mPAP), mean mitral pressure difference (mMVP)] at the time of admission and after the treatment, and the serum levels of CRP and MMP-9 were statistically compared between the two groups after the treatment. Results The total effective rate was higher in the study group than in the control group [92.68% (38/41) vs. (68.29%, 28/41)], with a statistical difference (P 0.05]. Conclusions Tirofiban combined with metoprolol for acute myocardial infarction is effective and safe and can effectively reduce the average pulmonary pressure and mitral valve pressure difference, improve hemodynamic status, and decrease the serum levels of MMP-9 and CRP, so it is worth being generalized. Key words: Tirofiban; Metoprolol; Acute myocardial infarction; Hemodynamics; MMP-9; CRP